LIPO Latest Quarter's Earnings
| Announce Date | 03/27/2025 |
| EPS Normalized Actual | $-1.19 (Beat by $1.24) |
| EPS GAAP Actual | $-1.19 (Beat by $1.24) |
| Revenue Actual | $0.12939B |
| Revenue Surprise | Beat by $129.39M |
Upcoming Quarter's Earnings
| Announce Date | 12/31/1969 (Pre-Market) |
| EPS Normalized Estimate | $ |
| EPS GAAP Estimate | $ |
| Revenue Estimate | $0B |
Annual EPS Estimate
| Fiscal Period Ending | EPS Estimate | Forward PE | Low | High | # of Analysts |
|---|---|---|---|---|---|
| Dec 2029 | 2.53 | 0.34 | 2.53 | 2.53 | 1 |
| Dec 2028 | 0.41 | 2.12 | 0.41 | 0.41 | 0 |
Quarterly EPS History
| Period | EPS | Beat / Miss | Revenue | YoY | Beat / Miss |
|---|---|---|---|---|---|
| FQ1 2025 (Mar 2025) | -0.64 | -0.64 | 0.12939B | -12.74% | 129.39M |
| FQ4 2024 (Dec 2024) | -1.37 | -2.91141 | 0.000173666B | -137389.2% | 0.02M |
| FQ3 2024 (Sep 2024) | -129.09 | -130.43259 | 0.08038B | -29.45% | 80.23M |
| FQ2 2024 (Jun 2024) | -0.12 | -1.46259 | 0.136431B | 21.81% | -76.92M |
| FQ1 2024 (Mar 2024) | -163.43 | -165.00645 | 0.14588B | 19.08% | -40.8M |
| FQ4 2023 (Dec 2023) | -770.65 | -772.73841 | 0.238772B | 99.92% | 78.76M |
| FQ3 2023 (Sep 2023) | -230.04 | -231.42812 | 0.104051B | 100% | -29.29M |
| FQ2 2023 (Jun 2023) | -267.88 | -269.07229 | 0.106676B | 100% | 0M |
Quarterly Estimates Summary
FQ4 Announce Date
12/31/1969 (Pre-Market)
Consensus EPS Estimates
Consensus Revenue Estimates
0B
Consensus EPS Estimates
| Fiscal Period Ending | EPS Estimate | YoY Growth(%) | Low | High | # of Analysts |
|---|
Consensus Revenue Estimates
| Fiscal Period Ending | Revenue Estimate | YoY Growth(%) | Low | High | # of Analysts |
|---|
Quarterly Estimates Revisions
EPS # of Up Revisions
4
EPS # of Down Revisions
4
Revenue # of Up Revisions
6
Revenue # of Down Revisions
3
Consensus EPS Revision Trend
| Fiscal Period Ending | EPS Estimate | YoY Growth | Low | High | # of Analysts |
|---|---|---|---|---|---|
| FQ4 2021 (Dec 2021) | 0.41 | -12.52% | 0.39 | 0.48 | 20 |
| FQ1 2022 (Mar 2022) | 0.59 | 6.89% | 0.55 | 0.62 | 15 |
| FQ2 2022 (Jun 2022) | 0.70 | 2.62% | 0.61 | 0.74 | 15 |
| FQ3 2022 (Sep 2022) | 0.68 | 4.62% | 0.65 | 0.70 | 15 |
Consensus Revenue Revision Trend
| Fiscal Period Ending | EPS Estimate | YoY Growth | Low | High | # of Analysts |
|---|---|---|---|---|---|
| FQ4 2021 (Dec 2021) | 0.41 | -12.52% | 0.39 | 0.48 | 20 |
| FQ1 2022 (Mar 2022) | 0.59 | 6.89% | 0.55 | 0.62 | 15 |
| FQ2 2022 (Jun 2022) | 0.70 | 2.62% | 0.61 | 0.74 | 15 |
| FQ3 2022 (Sep 2022) | 0.68 | 4.62% | 0.65 | 0.70 | 15 |
Earnings Surprise Summary
EPS # of Beats
0
EPS # of Misses
8
EPS # of in-lines
0
Revenue # of Beats
4
Revenue # of Misses
3
Revenue # of in-lines
1
Earnings Surprise (EPS) - Actual vs Consensus
| Earnings Date | EPS Estimate | EPS Actual | Surprise | Surprise % |
|---|---|---|---|---|
| FQ1 2025 (Mar 2025) | -0.64 | -0.64 | 100% | |
| FQ4 2024 (Dec 2024) | 1.54141 | -1.37 | -2.91141 | 212.51% |
| FQ3 2024 (Sep 2024) | 1.34259 | -129.09 | -130.43259 | 101.04% |
| FQ2 2024 (Jun 2024) | 1.34259 | -0.12 | -1.46259 | 1218.83% |
| FQ1 2024 (Mar 2024) | 1.57645 | -163.43 | -165.00645 | 100.96% |
| FQ4 2023 (Dec 2023) | 2.08841 | -770.65 | -772.73841 | 100.27% |
| FQ3 2023 (Sep 2023) | 1.38812 | -230.04 | -231.42812 | 100.6% |
| FQ2 2023 (Jun 2023) | 1.19229 | -267.88 | -269.07229 | 100.45% |
Revenue Surprise - Actual vs Consensus
| Earnings Date | Revenue Estimate | Revenue Actual | Surprise | Surprise % |
|---|---|---|---|---|
| FQ1 2025 (Mar 2025) | $0B | $0.13B | $129.39M | 100% |
| FQ4 2024 (Dec 2024) | $0B | $0B | $0.02M | 12.26% |
| FQ3 2024 (Sep 2024) | $0B | $0.08B | $80.23M | 99.81% |
| FQ2 2024 (Jun 2024) | $0.21B | $0.14B | $-76.92M | -56.38% |
| FQ1 2024 (Mar 2024) | $0.19B | $0.15B | $-40.8M | -27.97% |
| FQ4 2023 (Dec 2023) | $0.16B | $0.24B | $78.76M | 32.98% |
| FQ3 2023 (Sep 2023) | $0.13B | $0.1B | $-29.29M | -28.15% |
| FQ2 2023 (Jun 2023) | $0.11B | $0.11B | $0M | 0% |
LIPO Ratings Summary
LIPO Quant Ranking
